The adoption of PSMA PET/CT has resulted in a profound transformation of PCa management since its FDA approval and addition to various international cancer management guidelines (Supplemental Table 2) in recent years [13, 18–23]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.